Sagimet Biosciences Inc.: Oppenheimer raises target price to $38 from $33
SGMT•Oppenheimer raised its target price for Sagimet Biosciences to $38 from $33.
Related News
US wireless carriers name Paul Roth interim CEO for satellite connectivity venture
TMUS•
Aluminium falls to a 12-week low on stronger dollar
RIO•
LTC Properties buys three seniors housing communities for nearly $160 million
LTC•
FedEx completes sale of FedEx Supply Chain to CMA CGM for $1.4 billion enterprise value
FDX•
If a bruising third quarter can’t halt Wall Street, what can?
SPY•